This includes deciphering the precise mechanisms by which NF-κB differentially governs GSC identity versus immune suppression, identifying biomarkers that predict NF-κB dependency in GBM subtypes, and leveraging single-cell and spatial transcriptomic technologies to uncover cell-type-specific NF-κB circuits. The gene discussed is NFKB1; the disease is glioblastoma.